Table 3 CellTiter-Glo® and microscopic evaluation of a small subset (n = 25) of an FDA-approved compound library. Values of % reduced viability of compound-treated NTS relative to the controls were based on average luminescence for CellTiter-Glo® (subtracted from background) and on average viability scores for the microscopic evaluation.
% reduced viability relative to controls | ||
|---|---|---|
Compound | CellTiter-Glo® | Microscopic Evaluation |
acemetacin | 0 | 11.1 |
benzalkonium chloride | 94.9 | 100 |
cefpodoxime proxetil | 0 | 0 |
clofazimine | 85.2 | 100 |
clofibric acid | 0 | 0 |
docosanol | 0 | 0 |
docusate sodium | 0 | 0 |
ecamsule triethanolamine | 0 | 0 |
eletriptan hydrobromide | 0 | 0 |
etidronate disodium | 0 | 0 |
flumazenil | 0.5 | 0 |
lomerazine hydrochloride | 78.6 | 100 |
methylbenzethonium chloride | 84.5 | 100 |
nicardipine hydrochloride | 76.8 | 88.9 |
perhexiline maleate | 94.5 | 100 |
pipamperone | 0 | 0 |
pipemidic acid | 0 | 0 |
quinine ethyl carbonate | 0 | 0 |
ritodrine hydrochloride | 0 | 0 |
saccharin | 0 | 0 |
spiramycin | 0 | 0 |
sulpiride | 0 | 0 |
tamoxifen citrate | 85.4 | 100 |
teicoplanin | 0 | 0 |
tetramizole hydrochloride | 0 | 0 |